Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ACADIA Pharmaceuticals Inc. (ACAD : NSDQ)
 
 • Company Description   
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as?dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.

Number of Employees: 514

 
 • Price / Volume Information   
Yesterday's Closing Price: $16.83 Daily Weekly Monthly
20 Day Moving Average: 1,806,664 shares
Shares Outstanding: 161.43 (millions)
Market Capitalization: $2,716.86 (millions)
Beta: 0.67
52 Week High: $28.06
52 Week Low: $15.16
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -21.13% -11.17%
12 Week -34.82% -28.34%
Year To Date -27.89% -11.90%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
12830 El Camino Real Suite 400
-
SAN DIEGO,CA 92130
USA
ph: 858-558-2871
fax: 858-558-2872
ir@acadia-pharm.com http://www.acadia-pharm.com
 
 • General Corporate Information   
Officers
Stephen R. Davis - Chief Executive Officer
Stephen R. Biggar - Chairman of the Board
Mark C. Schneyer - Executive Vice President and Chief Financial Offic
James K. Kihara - Vice President; Chief Accounting Officer and Contr
Julian C. Baker - Director

Peer Information
ACADIA Pharmaceuticals Inc. (CORR.)
ACADIA Pharmaceuticals Inc. (RSPI)
ACADIA Pharmaceuticals Inc. (CGXP)
ACADIA Pharmaceuticals Inc. (BGEN)
ACADIA Pharmaceuticals Inc. (GTBP)
ACADIA Pharmaceuticals Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 004225108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 161.43
Most Recent Split Date: (:1)
Beta: 0.67
Market Capitalization: $2,716.86 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.41 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.11
Price/Cash Flow: -
Price / Sales: 5.51
EPS Growth
vs. Year Ago Period: -66.67%
vs. Previous Quarter: -159.26%
Sales Growth
vs. Year Ago Period: 8.37%
vs. Previous Quarter: -11.69%
ROE
03/31/22 - -40.52
12/31/21 - -29.79
09/30/21 - -32.74
ROA
03/31/22 - -31.01
12/31/21 - -23.17
09/30/21 - -25.71
Current Ratio
03/31/22 - 4.53
12/31/21 - 6.43
09/30/21 - 7.27
Quick Ratio
03/31/22 - 4.47
12/31/21 - 6.35
09/30/21 - 7.10
Operating Margin
03/31/22 - -43.50
12/31/21 - -34.67
09/30/21 - -40.38
Net Margin
03/31/22 - -43.50
12/31/21 - -34.67
09/30/21 - -40.38
Pre-Tax Margin
03/31/22 - -43.33
12/31/21 - -34.60
09/30/21 - -40.25
Book Value
03/31/22 - 2.76
12/31/21 - 3.36
09/30/21 - 3.53
Inventory Turnover
03/31/22 - 1.16
12/31/21 - 1.00
09/30/21 - 0.97
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©